(Q33678174)

28 July 2017

1 reference

title

Progress in determining the causes and treatment of multiple sclerosis (English)

1 reference

28 July 2017

0 references

Noseworthy JH

1

1 reference

PubMed ID

10392579

28 July 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

28 July 2017

1 reference

28 July 2017

399

1 reference

28 July 2017

A40-7

1 reference

28 July 2017

6738 Suppl

1 reference

https://scigraph.springernature.com/pub.10.1038/399a040

28 July 2017

0 references

cites work

The future of genetic studies of complex human diseases

1 reference

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

21 January 2018

1 reference

Multiple sclerosis clinical trials: old and new challenges

21 January 2018

1 reference

Epidemiologic evidence for multiple sclerosis as an infection

21 January 2018

1 reference

Clinical viral infections and multiple sclerosis.

21 January 2018

1 reference

Herpesviruses in multiple sclerosis

21 January 2018

1 reference

Plaque-associated expression of human herpesvirus 6 in multiple sclerosis

21 January 2018

1 reference

Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

21 January 2018

1 reference

Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and children

21 January 2018

1 reference

Herpes simplex virus in postmortem multiple sclerosis brain tissue

21 January 2018

1 reference

Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients

21 January 2018

1 reference

Genetic epidemiology of multiple sclerosis

21 January 2018

1 reference

Genetic epidemiology of multiple sclerosis.

21 January 2018

1 reference

Genetics of multiple sclerosis [published erratum appears in Hum Mol Genet 1997 Nov;6(12):2189]

21 January 2018

1 reference

Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group.

21 January 2018

1 reference

A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group

21 January 2018

1 reference

Multiple sclerosis. More genes versus environment

21 January 2018

1 reference

The genetic analysis of multiple sclerosis

21 January 2018

1 reference

Strategies to identify genes for complex diseases

21 January 2018

1 reference

A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22

21 January 2018

1 reference

A full genome search in multiple sclerosis

21 January 2018

1 reference

Genomewide scan of multiple sclerosis in Finnish multiplex families

21 January 2018

1 reference

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

21 January 2018

1 reference

Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.

21 January 2018

1 reference

Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture

21 January 2018

1 reference

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease

21 January 2018

1 reference

Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.

21 January 2018

1 reference

Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions.

21 January 2018

1 reference

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

21 January 2018

1 reference

Ultrastructural study of remyelination in an experimental lesion in adult cat spinal cord

21 January 2018

1 reference

Mechanisms of damage and repair in multiple sclerosis--a review

21 January 2018

1 reference

Future options for therapies to limit damage and enhance recovery

21 January 2018

1 reference

Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis

21 January 2018

1 reference

Evidence for a “dying‐back” gliopathy in demyelinating disease

21 January 2018

1 reference

Virus-induced demyelination in mice: "dying back" of oligodendrocytes

21 January 2018

1 reference

Axonal damage in acute multiple sclerosis lesions.

21 January 2018

1 reference

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis.

21 January 2018

1 reference

MRI dynamics of brain and spinal cord in progressive multiple sclerosis

21 January 2018

1 reference

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

21 January 2018

1 reference

Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis

21 January 2018

1 reference

A serial study of new MS lesions and the white matter from which they arise

21 January 2018

1 reference

Central motor conduction time in progressive multiple sclerosis. Correlations with MRI and disease activity.

21 January 2018

1 reference

A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop

21 January 2018

1 reference

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

21 January 2018

1 reference

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial

21 January 2018

1 reference

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

21 January 2018

1 reference

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

21 January 2018

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

21 January 2018

1 reference

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis.

21 January 2018

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

The small heat-shock protein αB-crystallin as candidate autoantigen in multiple sclerosis

21 January 2018

1 reference

A population-based study of multiple sclerosis in twins

21 January 2018

1 reference

7 January 2021

More mayhem from molecular mimics

1 reference

7 January 2021

A very high level of crossreactivity is an essential feature of the T-cell receptor

1 reference

7 January 2021

Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction.

1 reference

7 January 2021

A POSSIBLE MENDELIAN EXPLANATION FOR A TYPE OF INHERITANCE APPARENTLY NON-MENDELIAN IN NATURE

1 reference

7 January 2021

Mapping genetic susceptibility to multiple sclerosis

1 reference

7 January 2021

Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group

1 reference

7 January 2021

A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group

1 reference

7 January 2021

Multiple loci for multiple sclerosis

1 reference

7 January 2021

A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2

1 reference

7 January 2021

Proton magnetic resonance spectroscopy in multiple sclerosis

1 reference

7 January 2021

Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis

1 reference

7 January 2021

Spinal cord atrophy and disability in multiple sclerosis

1 reference

7 January 2021

Multiple sclerosis: remyelination of nascent lesions

1 reference

7 January 2021

A proliferative adult human oligodendrocyte progenitor

1 reference

7 January 2021

Immunoglobulins promote remyelination in the central nervous system

1 reference

7 January 2021

The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination

1 reference

7 January 2021

Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images

1 reference

7 January 2021

Multiple sclerosis: use of MRI in evaluating new therapies

1 reference

7 January 2021

Statistical methods for evaluating multiple sclerosis therapies

1 reference

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

7 January 2021

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

7 January 2021

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

7 January 2021

Perforin-dependent neurologic injury in a viral model of multiple sclerosis.

1 reference

7 January 2021

Identifiers

DOI

10.1038/399A040

1 reference

PubMed ID

10392579

Dimensions Publication ID

28 July 2017

0 references

1 reference

PubMed ID

10392579